Nonlinear analysis of partial dopamine agonist effects on cAMP in C6 glioma cells

Journal of Pharmacological and Toxicological Methods

Volumn 45, Issue 1, 2001, Pages 17-37

  Avalos, Melva ^a   Mak, Chun ^a,b   Randall, Patrick K ^a   Trzeciakowski, Jerome P ^c   Abell, Creed ^a   Kwan, Sau Wah ^a   Wilcox, Richard E ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

Adenylate cyclase; cAMP; Dopamine receptor; Partial agonist; Recombinant receptor; Second messenger

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; APOMORPHINE; CYCLIC AMP; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; PARTIAL AGONIST; QUINELORANE; ROTIGOTINE; ROXINDOLE; TALIPEXOLE; TERGURIDE; TIOSPIRONE;

ANALYTIC METHOD; ANIMAL CELL; ARTICLE; CALCULATION; CONTROLLED STUDY; DISSOCIATION CONSTANT; DOSE RESPONSE; DRUG EFFICACY; GLIOBLASTOMA; GLIOMA CELL; MODULATION; NONHUMAN; NONLINEAR SYSTEM; RAT; VALIDATION PROCESS;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; AZEPINES; CLOZAPINE; CYCLIC AMP; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FENOLDOPAM; GLIOMA; HALOPERIDOL; HUMANS; INDOLES; KINETICS; LISURIDE; MODELS, STATISTICAL; MONTE CARLO METHOD; NONLINEAR DYNAMICS; PYRIDINES; QUINOLINES; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SPIRO COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 0034908797     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8719(01)00118-6     Document Type: Article

References (61)

1. Receptors and dormant receptors - Messengers and opportunistic ligands
2. Dopamine D-2 agonists with high and low efficacies: Differentiation by behavioural techniques
3. Interactions between effectors linked to serotonin receptors
4. Pleiotropic behavior of 5-HT2A and 5-HT2C receptor agonists
5. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: Evidence for agonist-directed trafficking of receptor stimulus
6. Novel actions of inverse agonists on 5-HT2C receptor systems
7. Cloning and expression of a rat D2 dopamine receptor cDNA
8. Behavioural profile of partial D2 dopamine receptor agonists: 1. Atypical inhibition of d-amphetamine-induced locomotor hyperactivity and stereotypy
9. The elusive nature of intrinsic efficacy
10. Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetralin, N-n-propyl-3-(3-hydroxyphenyl)piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors
11. Partial brain dopamine D2 receptor agonists in the treatment of schizophrenia
12. Glial cell-specific expression of the serotonin 2 receptor gene: Selective reactivation of a repressed promoter
13. Presence of both beta1- and beta2-adrenergic receptors in a single cell type
14. Agonist-receptor efficacy: I. Mechanisms of efficacy and receptor promiscuity
15. Agonist-receptor efficacy: II. Agonist trafficking of receptor signals
16. The classification of seven transmembrane receptors in recombinant expression systems
17. Efficacy in drug receptor theory: Outdated concept or under-valued tool?
18. Efficacy: Molecular mechanisms and operational method of measurement. A new algorhythm for the prediction of side effects
19. Intrinsic activity determinations at the dopamine D2 guanine nucleotide-binding protein-coupled receptor: Utilization of receptor state binding affinities
20. Comparison of the expression, transcription and genomic organization of D2 dopamine receptors in outbred and inbred strains of rat
21. Molecular cloning and expression of the rhesus macaque D1 dopamine receptor gene
22. Improved models for pharmacological null experiments: Calculation of drug efficacy at recombinant D1A dopamine receptors stably expressed in clonal cell lines
23. Relationship between receptor occupancy and response at striatal dopamine autoreceptor
24. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1 D-2 and serotonin2 pKi values
25. Pivotal role for aspartate-80 in the regulation of dopamine D2 receptor affinity for drugs and inhibition of adenylyl cyclase
26. Quantitative analysis of the selectivity of radioligands for subtypes of beta adrenergic receptors
27. Agonist and antagonist actions of antipsychotic agents at 5-HT (1A) receptors: A [35S]GTPyS binding study
28. Electrophysiological evaluation of a partial agonist of dopamine receptors
29. Simple pA2 estimation of partial agonists: Comparison with the Kaumann-Blinks method
30. Ontogeny of dopamine D1 and D2 receptor subtypes in rat basal ganglia: A quantitative autoradiographic study
31. A partial agonist model used in the allosteric modulation of the NMDA receptor
32. Review important concepts of receptor theory
33. Binding of [3H]SCH23390 in rat brain: Regional distribution and effects of assay conditions and GTP suggest interactions at a D1-like dopamine receptor
34. Therapeutic receptor-blocking concentrations of neuroleptics
35. Dopamine D1 receptor pharmacology
36. Sensitivity of dopamine D2 receptors following long-term treatment with roxindole
37. Dopamine auto- and postsynaptic receptors: Electrophysiological evidence for differential sensitivity to dopamine agonists
38. A modification of receptor theory. 1956
39. Single apomorphine pretreatment results in a rapid decline in high-affinity dopamine binding to the striatal dopamine D-2 receptor
40. Partial dopamine receptor agonists reverse behavioral, biochemical and neuroendocrine effects of neuroleptics in the rat: Potential treatment of extrapyramidal side effects
41. 1-(2-Alkanamidoethyl)-6-methoxyindole derivatives: A new class of potent indole melatonin analogues
42. The potential antipsychotic activity of the partial dopamine receptor agonist (+)N-0437
43. A method for normalizing drug responses to enhance reliability of parametric statistical tests
44. Stimulus amplification, efficacy, and the operational model: Part I. Binary complex occupancy mechanisms
45. Stimulus amplification, efficacy, and the operational model. Part II - Ternary complex occupancy mechanisms
46. Spare receptors and intrinsic activity: Studies with D1 dopamine receptor agonists
47. Short- and long-term heterologous sensitization of adenylate cyclase by D4 dopamine receptors
48. Characterization of 3H-serotonin (5-HT) binding and effects on the phosphoinositides (PI) turnover in cultured C6 glioma and N2 neuroblastoma cells from rodents
49. Behavioral sensitization following a single apomorphine pretreatment-selective effects on the dopamine release process
50. Dopamine
51. Introduction to neurotransmitters, receptors, signal transduction and second messengers
52. Receptor reserve at striatal dopamine receptors modulating the release of [3H]dopamine